GFAP and synucleinopathy: Emerging plasma biomarkers—such as GFAP and αSyn-SAA—as well as neuroimaging techniques, including MRI and FDG-PET, may aid in detecting additional pathologies implicated in disease progression, such as vascular brain injury, neuroinflammation, and α-synucleinopathy (Jack Jr.